Micro-cap stock primarily engaged in providing civil construction services, including a range of general contracting and project management services, hit a 10 percent upper circuit in the day’s trade upon receiving a new work order worth Rs. 14.50 Crores.
Price Action
With a market capitalization of Rs. 53.03 Crores, the shares of Conart Engineers Limited hit a 10 percent upper circuit in the day’s trade at Rs. 168.90 per equity share, from its previous day’s close price of Rs. 153.55. It has delivered a return of 250 percent in a year.
What Happened
Conart Engineers Limited has announced that it has received a new work order for the Construction of formulation facility of Apothecon Pharmaceutical Pvt Ltd. Vadodara for a consideration of Rs. 14.50 Crores and it will be completed within 11 months.
About the Company
Conart Engineers Limited is primarily engaged in providing civil construction services, including a range of general contracting and project management services for industrial, commercial, and residential construction projects. It serves sectors such as heavy machinery, pharmaceuticals, chemicals, textiles, and education.
Its general contracting services and project management services include cost monitoring and control, schedule development and control, subcontractor management, field engineering, cost estimating, change order evaluation, technology services, quality management/field inspections, and many others
Financials & Ratios
Its Revenue from operations grew by 37.76 percent YoY from Rs. 35.49 Crores in FY23 to Rs. 48.89 Crores in FY24, accompanied by profits of Rs. 1.97 Crores to Rs. 3.08 Crores.
In terms of Return ratios, it has reported a return on equity (ROE) of 10.4 percent and a return on capital employed (ROCE) of 11.6 percent. It has reported a debt-to-equity ratio of 0.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
